Puma Biotechnology (PBYI) Other Non Operating Income (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Other Non Operating Income came in at $130000.0 in Q1 2026, down 63.79% YoY from $359000.0 in Q1 2025, and up 118.81% on a QoQ basis from -$691000.0 in Q4 2025.
Powered by 
Analysis
Puma Biotechnology (PBYI) Other Non Operating Income (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 15 years of Other Non Operating Income data on file, last reported at $130000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 63.79% year-over-year to $130000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36000.0 (down 103.19% YoY) and the FY2025 annual result came in at $193000.0, down 77.61% from the prior year.
- Other Non Operating Income grew to $130000.0 in Q1 2026, from -$691000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $410000.0 in Q2 2025 to a low of -$691000.0 in Q4 2025.
- A 5-year average of $68058.8 and a median of $86000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income soared 368.92% — and 2025, when it slumped 357.84%.
- Tracing PBYI's Other Non Operating Income over 5 years: stood at -$204000.0 in 2022, then soared by 42.16% to -$118000.0 in 2023, then jumped by 327.12% to $268000.0 in 2024, then tumbled by 357.84% to -$691000.0 in 2025, then jumped by 118.81% to $130000.0 in 2026.
- The last three Other Non Operating Income figures came in at $130000.0 (Q1 2026), -$691000.0 (Q4 2025), and $115000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 486.99 Mn | 393.08 Mn | 44.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9,000.00 |
| Mar 31, 2026 | 130,000.00 |
| Dec 31, 2025 | 143,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 410,000.00 |
| Mar 31, 2025 | 359,000.00 |
| Dec 31, 2024 | 268,000.00 |
| Sep 30, 2024 | 347,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 91,000.00 |
| Dec 31, 2023 | 641,000.00 |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 86,000.00 |
| Mar 31, 2023 | -42,000.00 |
| Dec 31, 2022 | -204,000.00 |
| Sep 30, 2022 | 64,000.00 |
| Jun 30, 2022 | 62,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Sep 30, 2021 | -8.15 Mn |
| Jun 30, 2021 | 60,000.00 |